Article Text

Download PDFPDF
Clinical value of pre-operative scoring systems to predict leiomyosarcoma: results of a validation study in 177 patients from the NOGGO-REGSA Registry
  1. Mateja Condic1,
  2. Eva Katharina Egger1,
  3. Peter Hohenberger2,
  4. Christian Staerk3,
  5. Andreas Mayr3,
  6. Robert Armbrust4,
  7. Eva Roser4,
  8. Alexander Mustea1 and
  9. Jalid Sehouli4
  1. 1 Gynaecology and Gynecologic Oncology, University Hospital Bonn Clinic for Gynaecologic Oncology, Bonn, Germany
  2. 2 Division of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Centre, University of Heidelberg, Mannheim, Germany
  3. 3 Department of Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany
  4. 4 Department of Gynecology with Center for Oncological Surgery, Charite University Hospital Berlin, Berlin, Germany
  1. Correspondence to Dr Mateja Condic, Gynaecology and Gynecologic Oncology, University Hospital Bonn Clinic for Gynaecologic Oncology, 53127 Bonn, Germany; mateja.condic{at}ukbonn.de

Abstract

Objectives Benign leiomyomas are the most common uterine tumors. In contrast, uterine leiomyosarcomas are malignancies with a poor prognosis due to difficulties in early diagnosis and inappropriate surgical treatment. Most often they are diagnosed incidentally after surgery performed for treatment of leiomyoma. As the appropriate surgical treatment is crucial for survival of the patient, there is a high demand to predict leiomyosarcoma pre-operatively. Available scoring systems to discriminate leiomyoma from leiomyosarcoma are based on retrospective studies with limited numbers of patients and are not implemented in routine clinical practice.

Methods The aim of our study was to evaluate a recently published score—the pre-operative leiomyosarcoma (pLMS) score—to determine whether it would have been predictive of leiomyosarcoma in 177 patients from the NOGGO-REGSA study, a German register of histologically proven gynecological sarcoma detected during routine clinical investigation.

Results The threshold of the pLMS score for ‘leiomyosarcoma not probable’ (< −3) failed for 7.5% of the patients and the threshold ‘indicator for leiomyosarcoma’ (>+1) was true for 39.1% of the patients. 53.4% of the patients were attributed to the group ‘additional investigations are recommended’ (−3 to +1). The most relevant parameters in our analysis were suspicious sonography and rapid growth, but neither have been quantitatively defined.

Conclusion In our validation cohort, the pLMS score seems not to be a reliable tool to predict leiomyosarcoma and therefore we do not recommend its clinical implementation to identify leiomyosarcoma.

  • sarcoma
  • uterine neoplasms

Data availability statement

Data are available upon reasonable request. The data that supporting the findings of this study are available from the corresponding author upon reasonable request.

Statistics from Altmetric.com

Data availability statement

Data are available upon reasonable request. The data that supporting the findings of this study are available from the corresponding author upon reasonable request.

View Full Text

Footnotes

  • AM and JS contributed equally.

  • Contributors MC, Alexander Mustea and JS contributed to project development, data collection, data analysis and interpretation and manuscript writing, CS and Andreas Mayr contributed to data analysis and interpretation, manuscript writing/editing, EKE, PH, RA and ER contributed to data interpretation and manuscript editing. MC is acting as guarantor of the published study.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.